CN110520161A - 用于癌症选择性标记和靶向的触发器可激活的糖缀合物 - Google Patents

用于癌症选择性标记和靶向的触发器可激活的糖缀合物 Download PDF

Info

Publication number
CN110520161A
CN110520161A CN201880023821.3A CN201880023821A CN110520161A CN 110520161 A CN110520161 A CN 110520161A CN 201880023821 A CN201880023821 A CN 201880023821A CN 110520161 A CN110520161 A CN 110520161A
Authority
CN
China
Prior art keywords
compound according
compound
alkyl
amino
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880023821.3A
Other languages
English (en)
Chinese (zh)
Inventor
程建军
蔡恺珉
于晋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of CN110520161A publication Critical patent/CN110520161A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880023821.3A 2017-02-10 2018-02-12 用于癌症选择性标记和靶向的触发器可激活的糖缀合物 Pending CN110520161A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762457597P 2017-02-10 2017-02-10
US62/457597 2017-02-10
PCT/US2018/017802 WO2018148650A1 (en) 2017-02-10 2018-02-12 Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Publications (1)

Publication Number Publication Date
CN110520161A true CN110520161A (zh) 2019-11-29

Family

ID=63107851

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880023821.3A Pending CN110520161A (zh) 2017-02-10 2018-02-12 用于癌症选择性标记和靶向的触发器可激活的糖缀合物

Country Status (6)

Country Link
US (1) US11299509B2 (https=)
EP (1) EP3595729A4 (https=)
JP (1) JP2020507584A (https=)
KR (1) KR20190126314A (https=)
CN (1) CN110520161A (https=)
WO (1) WO2018148650A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161452A1 (zh) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 缀合物及其用途
WO2023078464A1 (zh) * 2021-11-08 2023-05-11 上海弼领生物技术有限公司 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
CN116655715A (zh) * 2023-07-27 2023-08-29 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
IL264557B2 (en) 2016-08-02 2024-01-01 Harvard College Biological agents for regulating immune responses
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting
WO2020061129A1 (en) * 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US20220251126A1 (en) * 2019-08-05 2022-08-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Anticancer agents
WO2021061837A1 (en) 2019-09-23 2021-04-01 President And Fellows Of Harvard College Biomaterial-based antigen free vaccine and the use thereof
WO2021155297A1 (en) * 2020-01-29 2021-08-05 President And Fellows Of Harvard College Methods for labeling and targeting cells
CN120380004A (zh) * 2022-12-08 2025-07-25 杭州瑞奥生物医药有限公司 单糖、药物组合物及诊断和治疗应用
CN116239640B (zh) * 2023-01-19 2024-03-08 中国药科大学 吉西他滨前药及其医药用途
CN121889407A (zh) * 2023-08-15 2026-04-17 杭州瑞奥生物医药有限公司 可被aldh活化的功能化单糖、药物组合物及诊断和治疗应用
CN118603851A (zh) * 2024-05-22 2024-09-06 杭州瑞奥生物医药有限公司 一种检测细胞表面叠氮的两步法荧光标记流式方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630351B1 (en) * 1999-06-07 2003-10-07 Mirus Corporation Compositions and methods for drug delivery using pH sensitive molecules
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
US9321796B2 (en) 2012-06-28 2016-04-26 Universiteit Gent Galactopyranosyl derivatives useful as medicaments
CN105142672B (zh) * 2012-10-23 2019-04-05 西纳福克斯股份有限公司 经修饰的抗体、抗体-缀合物及其制备方法
US9943624B2 (en) 2012-11-30 2018-04-17 University Of Massachusetts Multi-functional surface coating of implants
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9695189B2 (en) * 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015021305A1 (en) 2013-08-09 2015-02-12 The Research Foundation For The State Univeristy Of New York Cancer cell specific imaging probes and methods of use
US10550190B2 (en) * 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
US10335495B2 (en) 2014-12-04 2019-07-02 Celgene Corporation Biomolecule conjugates
PT3250237T (pt) * 2015-01-30 2021-06-30 Sutro Biopharma Inc Derivados de hemiasterlina para conjugação e terapêutica
KR20180058737A (ko) 2015-10-07 2018-06-01 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 암 선택적 표지화 및 표적화를 위한 트리거-활성화 대사성 당 전구체
US11299509B2 (en) 2017-02-10 2022-04-12 The Board Of Trustees Of The University Of Illinois Trigger-activatable sugar conjugates for cancer-selective labeling and targeting

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161452A1 (zh) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 缀合物及其用途
WO2023078464A1 (zh) * 2021-11-08 2023-05-11 上海弼领生物技术有限公司 一种基于ε-聚-L-赖氨酸的药物偶联物、其中间体及其应用
CN116655715A (zh) * 2023-07-27 2023-08-29 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途
CN116655715B (zh) * 2023-07-27 2023-10-20 北京炫景瑞医药科技有限公司 一种GalNAc衍生物、缀合物、组合物以及它们的用途

Also Published As

Publication number Publication date
EP3595729A1 (en) 2020-01-22
US20190367550A1 (en) 2019-12-05
JP2020507584A (ja) 2020-03-12
WO2018148650A1 (en) 2018-08-16
KR20190126314A (ko) 2019-11-11
EP3595729A4 (en) 2022-01-12
US11299509B2 (en) 2022-04-12

Similar Documents

Publication Publication Date Title
CN110520161A (zh) 用于癌症选择性标记和靶向的触发器可激活的糖缀合物
CN108699095B (zh) 用于癌症选择性标记和靶向的触发子可活化代谢糖前体
CA2799773C (fr) Nouveaux bras autoreactifs et prodrogues les comprenant
CA2695297C (en) Substituted cc-1065 analogs and their conjugates
CN114555610A (zh) 硼酸酯前药及其用途
JP7425606B2 (ja) 四級化ニコチンアミドアデニンジヌクレオチドサルベージ経路阻害剤コンジュゲート
JP2001501596A (ja) バイオコンジュゲートおよび生物学的活性剤の送達
JP2022537543A (ja) 高速で且つ効率的なクリック放出の為の化合物
HUE035798T2 (en) CC-1065 analogues and conjugates
CN105407920A (zh) 靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
WO2022022649A1 (zh) 一种双药链接组装单元及双药靶向接头-药物偶联物
JP2002516878A (ja) テキサフィリン結合体およびその使用
CN106572991A (zh) 用于克服铂耐受性的德克萨卟啉‑pt(iv)缀合物及组合物
CN102803228B (zh) 酸不稳定触发子单元
US11591357B2 (en) Payload and linker designs for platinum-acridine anticancer agents and methods thereof
CN113365969A (zh) 含有邻苯二甲醛的连接体及其用于制备抗体-药物缀合物的用途
CN113321698B (zh) 一种单甲基澳瑞他汀e前药及其制备方法和应用
Wang et al. Synthesis and cytotoxicity of a biotinylated CC-1065 analogue
KR20250174687A (ko) 세포독성제를 전달하기 위한 항체-약물 접합체
JP2026513350A (ja) カンプトテシン誘導体の抗体－薬物コンジュゲートおよびその使用
KR20260028651A (ko) 엽산-약물 접합체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
Cartwright The design and synthesis of duocarmycin-based conjugates for targeted delivery to tumours
HK40065994A (zh) 含叔胺药物物质的靶向递送
HK40074614A (en) Boronic ester prodrugs and uses thereof
Wang et al. A Dual-mechanism Targeted Cross-convergence Prodrug Activation Strategy Enabled by Biological Stimulus Amplification towards Precision Cancer Therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191129